Deals channel feed – Endpoints News

Deals channel feed

Biogen taps digital therapeutics biotech for music-based therapy to help people with MS improve their walking

4 years ago

Illumina and Deerfield link arms to drive 'genomics-first' drug discovery

4 years ago

Big Pharma is rich. So much so, their coffers could buy more than 600 biotechs

4 years ago

Intercept sells ex-US rights to PBC drug as it gears up for a second-chance shot at NASH

4 years ago

Jazz doubles down on sleep disorders, putting down $50M cash to pluck Sumitomo drug for the pipeline

4 years ago

In wake of massive year-over-year growth, Moderna reserves its buyers seat at the global deals table

4 years ago

Novotech extends arms into US with acquisition of a South Carolina CRO

4 years ago

An upstart protein degradation contender adds Merck KGaA and Bristol Myers to its list of Big Pharma backers

4 years ago

As Biogen hunts for a turnaround CEO, execs sketch out a hazy look at an uncertain new future

4 years ago

Genentech-partnered Genesis Therapeutics inks newest AI discovery deal with Eli Lilly

4 years ago

GSK beat six other companies to the Sierra deal table and prevailed after initial $46 per share bid

4 years ago

Biotech’s biggest investor is prepping a whopping $4.75B wager on the future of the industry

4 years ago

Gilead joins a lineup of Big Pharma partners betting big on TriNKETs, with a $300M cash ante to get started on a 5T4

4 years ago

Fake news? Narcan maker forced to refute licensing deal after wire service apparently duped by false announcement

4 years ago

As its slide stretches into a second year, Zymeworks faces takeover bid

4 years ago

Big Pharma CEOs assess the BD landscape in biotech: Albert Bourla is staying focused on 2025-2030

4 years ago

More molecular glue: Plexium pens AbbVie pact months after Amgen deal

4 years ago

Caladrius’ 16-year rocky history bends again in Cend merger; After Cellectis, China JV pacts, Cytovia inks SPAC deal

4 years ago

Amgen kicks back I/O drug at center of $500M deal, leaving biotech partner alone to ponder next steps

4 years ago

Sanofi offloads French rights for antipsychotic to neighboring pharma

4 years ago

Vivo Capital pitches $60M to bring Arrowhead's RNAi meds to China via joint venture

4 years ago

Sanofi offloads two late-stage drugs to virtually unknown neuro and psychedelic biotech

4 years ago

FTC requires Hikma to let go of steroid drug as part of $375M acquisition of Custopharm

4 years ago

'Timing couldn't be better': An ex-generics maker goes SPAC route with blank check intended for sports market

4 years ago

First page Previous page 60 61 626364 65 66 Next page Last page